ABEONA THERAPEUTICS INC. 8-K

What Happened

• On March 9, 2026, Abeona Therapeutics, Inc. (ABEO) filed a Current Report on Form 8-K (Item 8.01) to announce a press release titled “Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch.” The press release is attached to the filing as Exhibit 99.1.
• The company says the update highlights progress and “building momentum” in the commercial rollout of ZEVASKYN, its product now in commercial launch.

Key Details

• Filing date: March 9, 2026 (Form 8-K, Item 8.01 — Other Events).
• Press release title: “Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch.”
• Exhibit included: Exhibit 99.1 (the March 9, 2026 press release) is incorporated by reference into the 8-K.

Why It Matters

• A business update focused on a commercial launch signals the company is shifting toward market commercialization; investors should watch for follow-up disclosures with concrete performance metrics (sales, revenue, prescribing or uptake data) that could affect quarterly results.
• This 8-K does not provide financial figures or guidance; it primarily announces the company's public update. Retail investors should look for subsequent filings, press releases, or quarterly reports for revenue, earnings, or other measurable indicators of ZEVASKYN’s commercial traction.